| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fibroblast Growth Factor 2 | 28 | 2005 | 592 | 2.630 |
Why?
|
| Recovery of Function | 25 | 2023 | 2979 | 1.710 |
Why?
|
| Cerebral Infarction | 18 | 2007 | 983 | 1.190 |
Why?
|
| Brain Ischemia | 22 | 2020 | 3049 | 1.020 |
Why?
|
| Stroke | 24 | 2023 | 9757 | 0.960 |
Why?
|
| Cerebrovascular Disorders | 16 | 1999 | 1474 | 0.910 |
Why?
|
| Neuroprotective Agents | 8 | 2012 | 957 | 0.830 |
Why?
|
| Motor Cortex | 12 | 2023 | 1006 | 0.760 |
Why?
|
| Infarction, Middle Cerebral Artery | 7 | 2015 | 485 | 0.730 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2012 | 103 | 0.680 |
Why?
|
| GAP-43 Protein | 8 | 2003 | 152 | 0.450 |
Why?
|
| Rats | 50 | 2015 | 23742 | 0.430 |
Why?
|
| Rats, Sprague-Dawley | 26 | 2015 | 8181 | 0.420 |
Why?
|
| Bone Morphogenetic Proteins | 4 | 2005 | 842 | 0.410 |
Why?
|
| Brain Injuries | 9 | 2020 | 2053 | 0.400 |
Why?
|
| Ischemic Attack, Transient | 8 | 2010 | 882 | 0.350 |
Why?
|
| Nerve Growth Factors | 4 | 1997 | 564 | 0.340 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2009 | 214 | 0.310 |
Why?
|
| Psychomotor Performance | 7 | 2021 | 1881 | 0.300 |
Why?
|
| Hand Strength | 4 | 2018 | 456 | 0.290 |
Why?
|
| Brain | 31 | 2019 | 27112 | 0.280 |
Why?
|
| Transforming Growth Factor beta | 4 | 2005 | 1961 | 0.280 |
Why?
|
| Motor Activity | 8 | 2012 | 2715 | 0.280 |
Why?
|
| 4-Aminopyridine | 2 | 2020 | 80 | 0.270 |
Why?
|
| Behavior, Animal | 7 | 2019 | 1878 | 0.270 |
Why?
|
| Cerebral Cortex | 14 | 2020 | 5777 | 0.270 |
Why?
|
| Motor Skills | 3 | 2019 | 521 | 0.260 |
Why?
|
| Animals | 74 | 2020 | 168459 | 0.210 |
Why?
|
| Nerve Tissue Proteins | 9 | 2015 | 4414 | 0.210 |
Why?
|
| Neuregulin-1 | 2 | 2015 | 135 | 0.210 |
Why?
|
| Functional Laterality | 10 | 2016 | 2257 | 0.190 |
Why?
|
| Bone Morphogenetic Protein 7 | 4 | 2005 | 110 | 0.190 |
Why?
|
| Macaca mulatta | 8 | 2020 | 2329 | 0.180 |
Why?
|
| Amino Acids | 1 | 2007 | 1718 | 0.180 |
Why?
|
| DNA Fragmentation | 1 | 2001 | 237 | 0.180 |
Why?
|
| Erythropoietin | 1 | 2005 | 719 | 0.180 |
Why?
|
| Goldfish | 3 | 1989 | 65 | 0.170 |
Why?
|
| Disease Models, Animal | 12 | 2019 | 18252 | 0.170 |
Why?
|
| Movement Disorders | 3 | 2020 | 459 | 0.170 |
Why?
|
| Fibroblast Growth Factors | 3 | 1990 | 867 | 0.170 |
Why?
|
| Myelin Sheath | 2 | 2020 | 653 | 0.170 |
Why?
|
| Injections, Intraventricular | 4 | 2003 | 225 | 0.160 |
Why?
|
| Superoxide Dismutase | 2 | 1999 | 594 | 0.150 |
Why?
|
| Upper Extremity | 5 | 2023 | 657 | 0.150 |
Why?
|
| Cyprinidae | 2 | 1988 | 37 | 0.150 |
Why?
|
| Pyramidal Tracts | 1 | 2019 | 252 | 0.150 |
Why?
|
| Time Factors | 17 | 2015 | 39967 | 0.140 |
Why?
|
| Culture Media | 3 | 1989 | 897 | 0.140 |
Why?
|
| Brain Chemistry | 3 | 2001 | 960 | 0.140 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1999 | 461 | 0.130 |
Why?
|
| Inosine | 1 | 2016 | 130 | 0.130 |
Why?
|
| Optic Nerve | 3 | 1989 | 572 | 0.130 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2020 | 499 | 0.130 |
Why?
|
| Male | 72 | 2023 | 360804 | 0.130 |
Why?
|
| Cerebrovascular Circulation | 10 | 2001 | 2727 | 0.120 |
Why?
|
| Rats, Inbred Strains | 12 | 1992 | 2088 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 1600 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2001 | 1405 | 0.120 |
Why?
|
| Exosomes | 1 | 2019 | 424 | 0.110 |
Why?
|
| Thrombolytic Therapy | 2 | 2017 | 2064 | 0.110 |
Why?
|
| Injections, Intravenous | 4 | 2001 | 1379 | 0.110 |
Why?
|
| Reperfusion Injury | 2 | 1997 | 1023 | 0.110 |
Why?
|
| Language | 1 | 2023 | 1540 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2007 | 8002 | 0.110 |
Why?
|
| Bone Marrow Cells | 1 | 2020 | 2416 | 0.110 |
Why?
|
| Analysis of Variance | 6 | 2015 | 6228 | 0.100 |
Why?
|
| Potassium Channel Blockers | 1 | 2013 | 161 | 0.100 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1997 | 710 | 0.100 |
Why?
|
| Walking | 1 | 2020 | 1198 | 0.100 |
Why?
|
| Drug Administration Routes | 2 | 2005 | 150 | 0.100 |
Why?
|
| Thrombectomy | 1 | 2017 | 705 | 0.100 |
Why?
|
| Brain Infarction | 3 | 2015 | 290 | 0.100 |
Why?
|
| Dopamine | 8 | 1986 | 1607 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 10766 | 0.100 |
Why?
|
| Ubiquitins | 1 | 1993 | 366 | 0.100 |
Why?
|
| Rats, Wistar | 4 | 2001 | 1848 | 0.100 |
Why?
|
| Stem Cells | 2 | 2004 | 3522 | 0.100 |
Why?
|
| Forelimb | 3 | 2003 | 116 | 0.090 |
Why?
|
| Peptides | 2 | 1997 | 4358 | 0.090 |
Why?
|
| Norepinephrine | 6 | 1986 | 897 | 0.090 |
Why?
|
| Microglia | 3 | 2019 | 1361 | 0.090 |
Why?
|
| Optic Nerve Injuries | 2 | 1989 | 150 | 0.090 |
Why?
|
| Physical Therapy Modalities | 3 | 2018 | 532 | 0.090 |
Why?
|
| Axons | 3 | 1999 | 1674 | 0.090 |
Why?
|
| Tomography, Emission-Computed | 3 | 1984 | 1122 | 0.090 |
Why?
|
| Molecular Weight | 5 | 1999 | 2186 | 0.090 |
Why?
|
| Multigene Family | 1 | 1993 | 1076 | 0.090 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2009 | 32 | 0.080 |
Why?
|
| Cerebral Amyloid Angiopathy | 2 | 1996 | 895 | 0.080 |
Why?
|
| Corpus Striatum | 8 | 2000 | 1235 | 0.080 |
Why?
|
| Immunohistochemistry | 9 | 2004 | 11076 | 0.080 |
Why?
|
| Embryonic and Fetal Development | 1 | 1990 | 420 | 0.080 |
Why?
|
| Cisterna Magna | 2 | 1999 | 39 | 0.080 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2019 | 1642 | 0.080 |
Why?
|
| Research | 1 | 2017 | 1982 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2003 | 36426 | 0.080 |
Why?
|
| Humans | 65 | 2023 | 761504 | 0.080 |
Why?
|
| Neuronal Plasticity | 5 | 2018 | 1436 | 0.080 |
Why?
|
| Up-Regulation | 1 | 1997 | 4124 | 0.080 |
Why?
|
| Neurons | 9 | 2001 | 9463 | 0.080 |
Why?
|
| Recombinant Proteins | 5 | 2010 | 6534 | 0.080 |
Why?
|
| Dominance, Cerebral | 3 | 1984 | 623 | 0.070 |
Why?
|
| Hydroxydopamines | 1 | 1986 | 59 | 0.070 |
Why?
|
| Health Priorities | 1 | 2010 | 374 | 0.070 |
Why?
|
| Body Weight | 4 | 2005 | 4618 | 0.070 |
Why?
|
| Drug Administration Schedule | 3 | 2015 | 4853 | 0.070 |
Why?
|
| Arteries | 2 | 2001 | 1123 | 0.070 |
Why?
|
| National Health Programs | 1 | 2010 | 440 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2007 | 166 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 1997 | 3702 | 0.070 |
Why?
|
| Cell Count | 2 | 2003 | 1835 | 0.070 |
Why?
|
| Brachytherapy | 1 | 1994 | 1223 | 0.070 |
Why?
|
| Biogenic Amines | 1 | 1985 | 53 | 0.060 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1987 | 432 | 0.060 |
Why?
|
| Selection Bias | 1 | 2007 | 359 | 0.060 |
Why?
|
| Brain Damage, Chronic | 1 | 2006 | 267 | 0.060 |
Why?
|
| Patient Selection | 2 | 2007 | 4244 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 823 | 0.060 |
Why?
|
| Thioridazine | 1 | 1984 | 33 | 0.060 |
Why?
|
| Aging | 3 | 2020 | 8708 | 0.060 |
Why?
|
| Depressive Disorder | 3 | 1988 | 3728 | 0.060 |
Why?
|
| Biomedical Research | 2 | 2010 | 3429 | 0.060 |
Why?
|
| N-Methylaspartate | 3 | 1995 | 231 | 0.060 |
Why?
|
| Perceptual Disorders | 1 | 1986 | 198 | 0.060 |
Why?
|
| Radioisotopes | 2 | 1982 | 499 | 0.060 |
Why?
|
| Patient Education as Topic | 2 | 2010 | 2319 | 0.060 |
Why?
|
| Growth Substances | 2 | 2005 | 768 | 0.060 |
Why?
|
| Paresis | 2 | 2011 | 176 | 0.060 |
Why?
|
| Frontal Lobe | 2 | 1988 | 1420 | 0.060 |
Why?
|
| Brain Concussion | 1 | 2015 | 1404 | 0.060 |
Why?
|
| Cerebral Hemorrhage | 4 | 1996 | 2656 | 0.060 |
Why?
|
| Eye Proteins | 1 | 1987 | 633 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2005 | 748 | 0.050 |
Why?
|
| Bromodeoxyuridine | 1 | 2003 | 311 | 0.050 |
Why?
|
| Indium | 1 | 1982 | 47 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2009 | 1493 | 0.050 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 4 | 1986 | 63 | 0.050 |
Why?
|
| Lateral Ventricles | 1 | 2003 | 146 | 0.050 |
Why?
|
| Health Services Research | 1 | 2010 | 1812 | 0.050 |
Why?
|
| Hydroxyindoleacetic Acid | 4 | 1986 | 93 | 0.050 |
Why?
|
| Dentate Gyrus | 1 | 2003 | 164 | 0.050 |
Why?
|
| Neurology | 1 | 2010 | 780 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2005 | 629 | 0.050 |
Why?
|
| Drug Design | 1 | 2007 | 1048 | 0.050 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 11903 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 4063 | 0.050 |
Why?
|
| Fingers | 3 | 2000 | 507 | 0.050 |
Why?
|
| Animals, Newborn | 6 | 1995 | 2678 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2015 | 6240 | 0.050 |
Why?
|
| Nervous System Diseases | 4 | 1997 | 1666 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2022 | 2421 | 0.050 |
Why?
|
| Cardiovascular Agents | 1 | 2007 | 840 | 0.050 |
Why?
|
| Reference Values | 4 | 2000 | 4920 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2003 | 910 | 0.040 |
Why?
|
| Giant Cells | 1 | 2001 | 188 | 0.040 |
Why?
|
| Gene Expression | 1 | 1993 | 7581 | 0.040 |
Why?
|
| Carotid Artery Thrombosis | 1 | 1980 | 50 | 0.040 |
Why?
|
| Blood Volume | 1 | 2001 | 547 | 0.040 |
Why?
|
| Hemiplegia | 2 | 1997 | 136 | 0.040 |
Why?
|
| Caspase 1 | 1 | 2001 | 225 | 0.040 |
Why?
|
| Psychomotor Disorders | 1 | 2001 | 149 | 0.040 |
Why?
|
| Membrane Proteins | 5 | 2004 | 7856 | 0.040 |
Why?
|
| Drug Approval | 1 | 2007 | 814 | 0.040 |
Why?
|
| Infusions, Intravenous | 4 | 1999 | 2219 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2001 | 613 | 0.040 |
Why?
|
| Gliosis | 1 | 2020 | 245 | 0.040 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2001 | 282 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2007 | 1835 | 0.040 |
Why?
|
| Middle Cerebral Artery | 1 | 2001 | 275 | 0.040 |
Why?
|
| Serotonin | 6 | 1986 | 1041 | 0.040 |
Why?
|
| Extremities | 1 | 2005 | 867 | 0.040 |
Why?
|
| Neurotransmitter Agents | 1 | 1983 | 665 | 0.040 |
Why?
|
| Percussion | 2 | 2015 | 18 | 0.040 |
Why?
|
| Motor Neuron Disease | 1 | 1999 | 97 | 0.040 |
Why?
|
| Carbidopa | 1 | 2018 | 30 | 0.040 |
Why?
|
| Memory Disorders | 1 | 1986 | 1198 | 0.040 |
Why?
|
| Hepatitis | 1 | 2001 | 228 | 0.040 |
Why?
|
| Neurologic Manifestations | 1 | 1978 | 19 | 0.040 |
Why?
|
| Phosphoproteins | 2 | 1987 | 2448 | 0.040 |
Why?
|
| Epoetin Alfa | 1 | 2018 | 78 | 0.040 |
Why?
|
| Speech Therapy | 1 | 2018 | 57 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2006 | 929 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2001 | 731 | 0.040 |
Why?
|
| Epilepsies, Partial | 1 | 1982 | 431 | 0.040 |
Why?
|
| Antioxidants | 1 | 1986 | 1668 | 0.040 |
Why?
|
| Nerve Crush | 2 | 1988 | 77 | 0.040 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 1982 | 389 | 0.040 |
Why?
|
| Synaptophysin | 1 | 2018 | 139 | 0.040 |
Why?
|
| Visual Perception | 1 | 1986 | 1387 | 0.040 |
Why?
|
| Levodopa | 1 | 2018 | 221 | 0.040 |
Why?
|
| Genes, fos | 1 | 2018 | 176 | 0.040 |
Why?
|
| Caspases | 1 | 2001 | 879 | 0.040 |
Why?
|
| Pyridines | 3 | 1986 | 2875 | 0.040 |
Why?
|
| Hindlimb | 1 | 2000 | 513 | 0.040 |
Why?
|
| Brain Mapping | 4 | 2016 | 6630 | 0.040 |
Why?
|
| Microinjections | 1 | 1998 | 321 | 0.040 |
Why?
|
| Gerbillinae | 2 | 1996 | 87 | 0.040 |
Why?
|
| Entorhinal Cortex | 1 | 1999 | 287 | 0.040 |
Why?
|
| Occupational Therapy | 1 | 2018 | 139 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 2 | 1997 | 1624 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2004 | 1347 | 0.030 |
Why?
|
| Middle Aged | 24 | 2021 | 220895 | 0.030 |
Why?
|
| Blotting, Northern | 2 | 1996 | 1545 | 0.030 |
Why?
|
| Pyramidal Cells | 2 | 1997 | 369 | 0.030 |
Why?
|
| Oligodendroglia | 1 | 2020 | 538 | 0.030 |
Why?
|
| Umbilical Cord | 1 | 2018 | 177 | 0.030 |
Why?
|
| Female | 33 | 2023 | 392644 | 0.030 |
Why?
|
| Chorionic Gonadotropin | 1 | 2018 | 457 | 0.030 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2019 | 305 | 0.030 |
Why?
|
| Dexamethasone | 2 | 1988 | 1948 | 0.030 |
Why?
|
| Transducers | 1 | 1997 | 244 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 1667 | 0.030 |
Why?
|
| Dopamine Agonists | 1 | 2018 | 352 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2019 | 553 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 962 | 0.030 |
Why?
|
| Piperazines | 1 | 1986 | 2523 | 0.030 |
Why?
|
| Excitatory Amino Acids | 1 | 1995 | 17 | 0.030 |
Why?
|
| Coma | 1 | 1979 | 484 | 0.030 |
Why?
|
| Aged | 17 | 2021 | 169289 | 0.030 |
Why?
|
| Purpura | 1 | 1996 | 117 | 0.030 |
Why?
|
| In Situ Hybridization | 2 | 1996 | 1900 | 0.030 |
Why?
|
| Movement | 2 | 2000 | 1478 | 0.030 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2018 | 227 | 0.030 |
Why?
|
| Blood Pressure | 3 | 2001 | 8481 | 0.030 |
Why?
|
| Precipitin Tests | 1 | 1995 | 814 | 0.030 |
Why?
|
| Autoradiography | 1 | 1995 | 728 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2010 | 7967 | 0.030 |
Why?
|
| RNA, Messenger | 4 | 1996 | 12795 | 0.030 |
Why?
|
| Nervous System | 1 | 1997 | 545 | 0.030 |
Why?
|
| Registries | 1 | 2010 | 8224 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 1997 | 908 | 0.030 |
Why?
|
| Pia Mater | 1 | 1994 | 87 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2001 | 2919 | 0.030 |
Why?
|
| Nerve Regeneration | 1 | 1999 | 795 | 0.030 |
Why?
|
| Neuroglia | 1 | 1999 | 956 | 0.030 |
Why?
|
| Polyubiquitin | 1 | 1993 | 68 | 0.030 |
Why?
|
| Blood-Brain Barrier | 2 | 1999 | 1027 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 2231 | 0.030 |
Why?
|
| Hand | 1 | 1998 | 902 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2018 | 2048 | 0.030 |
Why?
|
| Biopolymers | 1 | 1993 | 184 | 0.030 |
Why?
|
| Guidelines as Topic | 2 | 2010 | 1386 | 0.030 |
Why?
|
| Thalamus | 2 | 2015 | 1045 | 0.030 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 3 | 1986 | 89 | 0.020 |
Why?
|
| Necrosis | 1 | 1996 | 1611 | 0.020 |
Why?
|
| Robotics | 1 | 2018 | 819 | 0.020 |
Why?
|
| Cell Survival | 2 | 1999 | 5791 | 0.020 |
Why?
|
| Echo-Planar Imaging | 1 | 1996 | 663 | 0.020 |
Why?
|
| Blood Platelets | 1 | 1982 | 2479 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2019 | 2790 | 0.020 |
Why?
|
| Electroencephalography | 3 | 2016 | 6225 | 0.020 |
Why?
|
| Anisotropy | 1 | 2015 | 1283 | 0.020 |
Why?
|
| Estradiol | 1 | 1998 | 1937 | 0.020 |
Why?
|
| Cells, Cultured | 6 | 1989 | 18965 | 0.020 |
Why?
|
| Adult | 17 | 2020 | 221177 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 1994 | 11118 | 0.020 |
Why?
|
| Neurotoxins | 1 | 1992 | 240 | 0.020 |
Why?
|
| Nitric Oxide | 2 | 1997 | 2135 | 0.020 |
Why?
|
| Iron | 1 | 2019 | 1793 | 0.020 |
Why?
|
| Mitogens | 1 | 1990 | 230 | 0.020 |
Why?
|
| Heparin | 1 | 1997 | 1634 | 0.020 |
Why?
|
| Linear Models | 1 | 2019 | 5871 | 0.020 |
Why?
|
| Equipment Design | 1 | 1997 | 3510 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2013 | 1572 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1989 | 1741 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 2001 | 1922 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1989 | 297 | 0.020 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2018 | 1472 | 0.020 |
Why?
|
| Hippocampus | 3 | 2015 | 3766 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 4511 | 0.020 |
Why?
|
| Heart Arrest | 1 | 1978 | 1514 | 0.020 |
Why?
|
| Immune Sera | 1 | 1988 | 606 | 0.020 |
Why?
|
| Chromatography, Gel | 1 | 1989 | 645 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2010 | 426 | 0.020 |
Why?
|
| Neurologic Examination | 2 | 2003 | 916 | 0.020 |
Why?
|
| Synaptosomes | 2 | 1986 | 116 | 0.020 |
Why?
|
| Technology | 1 | 2010 | 292 | 0.020 |
Why?
|
| Mice | 6 | 2005 | 81525 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 701 | 0.020 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1987 | 299 | 0.020 |
Why?
|
| Chemistry | 1 | 1987 | 347 | 0.020 |
Why?
|
| Electrophoresis | 1 | 1987 | 227 | 0.020 |
Why?
|
| Amygdala | 1 | 2015 | 1354 | 0.020 |
Why?
|
| Homovanillic Acid | 1 | 1986 | 75 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1987 | 507 | 0.020 |
Why?
|
| Cell Differentiation | 3 | 2004 | 11528 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2013 | 2078 | 0.020 |
Why?
|
| Muridae | 1 | 1986 | 56 | 0.020 |
Why?
|
| Oxidopamine | 1 | 1986 | 172 | 0.020 |
Why?
|
| Disease Progression | 1 | 2003 | 13506 | 0.020 |
Why?
|
| Aged, 80 and over | 6 | 2001 | 58976 | 0.020 |
Why?
|
| Carotid Artery, Internal | 2 | 1980 | 445 | 0.020 |
Why?
|
| Apraxias | 1 | 1986 | 59 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 2 | 1999 | 413 | 0.020 |
Why?
|
| Age Factors | 3 | 2017 | 18395 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2007 | 326 | 0.020 |
Why?
|
| Electromyography | 2 | 2002 | 1394 | 0.020 |
Why?
|
| Circadian Rhythm | 2 | 1988 | 2576 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2020 | 12341 | 0.020 |
Why?
|
| Intracranial Embolism and Thrombosis | 2 | 1982 | 144 | 0.020 |
Why?
|
| Quality of Life | 1 | 2007 | 13367 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 1986 | 335 | 0.020 |
Why?
|
| Apoptosis | 1 | 2001 | 9486 | 0.010 |
Why?
|
| Logistic Models | 1 | 2019 | 13255 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 15842 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 1997 | 4431 | 0.010 |
Why?
|
| Multiple Sclerosis | 1 | 2020 | 3220 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2007 | 629 | 0.010 |
Why?
|
| Endpoint Determination | 1 | 2007 | 590 | 0.010 |
Why?
|
| Electrochemistry | 1 | 1984 | 145 | 0.010 |
Why?
|
| History, 21st Century | 1 | 2010 | 1567 | 0.010 |
Why?
|
| Phenotype | 1 | 2022 | 16591 | 0.010 |
Why?
|
| Stereotyped Behavior | 1 | 1984 | 135 | 0.010 |
Why?
|
| Treatment Outcome | 3 | 2016 | 64680 | 0.010 |
Why?
|
| International Cooperation | 1 | 2010 | 1422 | 0.010 |
Why?
|
| Health Education | 1 | 2010 | 1052 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2007 | 793 | 0.010 |
Why?
|
| Cognition | 1 | 2021 | 6990 | 0.010 |
Why?
|
| Septal Nuclei | 1 | 1984 | 85 | 0.010 |
Why?
|
| Sex Factors | 1 | 2017 | 10552 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 3792 | 0.010 |
Why?
|
| Locomotion | 1 | 1986 | 388 | 0.010 |
Why?
|
| Space Perception | 1 | 1986 | 465 | 0.010 |
Why?
|
| Recruitment, Neurophysiological | 1 | 2002 | 33 | 0.010 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2003 | 1432 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 1505 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 1997 | 3979 | 0.010 |
Why?
|
| Oxygen Radioisotopes | 1 | 1982 | 75 | 0.010 |
Why?
|
| Comorbidity | 1 | 2017 | 10508 | 0.010 |
Why?
|
| Dystrophin | 1 | 2004 | 283 | 0.010 |
Why?
|
| Fluorine | 1 | 1982 | 83 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2017 | 9318 | 0.010 |
Why?
|
| History, 20th Century | 1 | 2010 | 2767 | 0.010 |
Why?
|
| Isoxazoles | 1 | 2004 | 232 | 0.010 |
Why?
|
| Cell Transplantation | 1 | 2004 | 472 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2007 | 981 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 658 | 0.010 |
Why?
|
| Nucleus Accumbens | 1 | 1984 | 366 | 0.010 |
Why?
|
| Compliance | 1 | 2001 | 100 | 0.010 |
Why?
|
| Hypercapnia | 1 | 2003 | 261 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1982 | 561 | 0.010 |
Why?
|
| Fatty Acids | 1 | 1989 | 1808 | 0.010 |
Why?
|
| Radionuclide Imaging | 2 | 1982 | 1972 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1990 | 6216 | 0.010 |
Why?
|
| Drug Industry | 1 | 2007 | 788 | 0.010 |
Why?
|
| Patient Discharge | 1 | 1994 | 3443 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1982 | 945 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1984 | 1541 | 0.010 |
Why?
|
| Tacrolimus | 1 | 2004 | 733 | 0.010 |
Why?
|
| Incidence | 1 | 1998 | 21353 | 0.010 |
Why?
|
| Rabbits | 2 | 1984 | 4772 | 0.010 |
Why?
|
| Analgesics | 1 | 1986 | 1070 | 0.010 |
Why?
|
| Hallucinations | 1 | 1982 | 366 | 0.010 |
Why?
|
| Hydrocortisone | 2 | 1988 | 1819 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2007 | 1664 | 0.010 |
Why?
|
| Systole | 1 | 2001 | 936 | 0.010 |
Why?
|
| Muscle Proteins | 1 | 2004 | 1154 | 0.010 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 1998 | 239 | 0.010 |
Why?
|
| Cell Death | 2 | 1995 | 1678 | 0.010 |
Why?
|
| Poisoning | 1 | 1979 | 252 | 0.010 |
Why?
|
| Drug Implants | 1 | 1998 | 230 | 0.010 |
Why?
|
| Sensation | 1 | 2000 | 337 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3688 | 0.010 |
Why?
|
| Internet | 1 | 2010 | 3092 | 0.010 |
Why?
|
| Piperidines | 1 | 1986 | 1656 | 0.010 |
Why?
|
| Pilot Projects | 2 | 2002 | 8631 | 0.010 |
Why?
|
| Spinal Puncture | 1 | 1979 | 282 | 0.010 |
Why?
|
| Health Policy | 1 | 2010 | 2684 | 0.010 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1983 | 746 | 0.010 |
Why?
|
| Touch | 1 | 2000 | 313 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 2295 | 0.010 |
Why?
|
| Public Health | 1 | 2010 | 2669 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 1844 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 1982 | 852 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 4 | 1996 | 20570 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1986 | 1545 | 0.010 |
Why?
|
| Water | 1 | 2003 | 1411 | 0.010 |
Why?
|
| Amnesia | 1 | 1978 | 255 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1998 | 614 | 0.010 |
Why?
|
| Cerebral Arteries | 1 | 1978 | 490 | 0.010 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 1 | 1995 | 34 | 0.010 |
Why?
|
| Malonates | 1 | 1995 | 43 | 0.010 |
Why?
|
| Spinal Cord Diseases | 1 | 1978 | 292 | 0.010 |
Why?
|
| Cats | 1 | 1997 | 975 | 0.010 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 1997 | 246 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1997 | 553 | 0.010 |
Why?
|
| Brain Death | 1 | 1978 | 357 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2004 | 2555 | 0.010 |
Why?
|
| Prognosis | 2 | 2010 | 29625 | 0.010 |
Why?
|
| Aorta | 1 | 1982 | 2042 | 0.010 |
Why?
|
| Blindness | 1 | 1978 | 584 | 0.010 |
Why?
|
| Tissue Distribution | 2 | 1989 | 2265 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 1982 | 1695 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 1997 | 930 | 0.010 |
Why?
|
| Prosencephalon | 1 | 1996 | 305 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1998 | 1967 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1994 | 260 | 0.010 |
Why?
|
| Psychotic Disorders | 1 | 1988 | 3223 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1982 | 2413 | 0.010 |
Why?
|
| Arterioles | 1 | 1994 | 250 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1997 | 748 | 0.010 |
Why?
|
| Quinolinic Acids | 1 | 1992 | 15 | 0.010 |
Why?
|
| Nerve Degeneration | 1 | 1997 | 748 | 0.010 |
Why?
|
| Quinolinic Acid | 1 | 1992 | 67 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2003 | 4159 | 0.010 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1998 | 1208 | 0.010 |
Why?
|
| Kainic Acid | 1 | 1992 | 203 | 0.010 |
Why?
|
| Administration, Topical | 1 | 1994 | 704 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 4174 | 0.010 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 1991 | 191 | 0.010 |
Why?
|
| Glutamates | 1 | 1992 | 389 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 1999 | 9000 | 0.010 |
Why?
|
| Oxygen | 1 | 1982 | 4227 | 0.010 |
Why?
|
| Glucose | 1 | 1982 | 4346 | 0.010 |
Why?
|
| Arginine | 1 | 1994 | 934 | 0.010 |
Why?
|
| Injections | 1 | 1993 | 830 | 0.010 |
Why?
|
| Body Temperature | 1 | 1993 | 781 | 0.010 |
Why?
|
| Vasodilation | 1 | 1994 | 962 | 0.010 |
Why?
|
| Postmenopause | 1 | 1998 | 2513 | 0.010 |
Why?
|
| Acylation | 1 | 1989 | 96 | 0.010 |
Why?
|
| Biological Assay | 1 | 1991 | 626 | 0.000 |
Why?
|
| Kidney | 1 | 2004 | 7048 | 0.000 |
Why?
|
| Liver | 1 | 2004 | 7529 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1989 | 659 | 0.000 |
Why?
|
| Memory | 1 | 1997 | 2188 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1994 | 1440 | 0.000 |
Why?
|
| Mice, Transgenic | 1 | 1999 | 9539 | 0.000 |
Why?
|
| Diencephalon | 1 | 1986 | 54 | 0.000 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1992 | 894 | 0.000 |
Why?
|
| Risk Factors | 1 | 1993 | 74206 | 0.000 |
Why?
|
| Glutamic Acid | 1 | 1992 | 1176 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 10194 | 0.000 |
Why?
|
| Telencephalon | 1 | 1986 | 142 | 0.000 |
Why?
|
| Hypothalamus | 1 | 1991 | 999 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1987 | 1302 | 0.000 |
Why?
|
| Embryo, Nonmammalian | 1 | 1989 | 906 | 0.000 |
Why?
|
| Acute Disease | 1 | 1996 | 7237 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1986 | 1141 | 0.000 |
Why?
|
| Somatosensory Cortex | 1 | 1989 | 512 | 0.000 |
Why?
|
| Affective Disorders, Psychotic | 1 | 1986 | 186 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1989 | 1085 | 0.000 |
Why?
|
| Blood | 1 | 1986 | 596 | 0.000 |
Why?
|
| Tail | 1 | 1984 | 91 | 0.000 |
Why?
|
| Tritium | 1 | 1984 | 708 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1983 | 6845 | 0.000 |
Why?
|
| Embryo, Mammalian | 1 | 1989 | 1675 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1984 | 1310 | 0.000 |
Why?
|
| Substantia Nigra | 1 | 1984 | 350 | 0.000 |
Why?
|
| False Negative Reactions | 1 | 1983 | 573 | 0.000 |
Why?
|
| Receptors, Cell Surface | 1 | 1991 | 2822 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 1997 | 14414 | 0.000 |
Why?
|
| Pregnancy | 2 | 1993 | 29874 | 0.000 |
Why?
|
| False Positive Reactions | 1 | 1983 | 957 | 0.000 |
Why?
|
| Fetus | 1 | 1987 | 1863 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 2001 | 39106 | 0.000 |
Why?
|
| United States | 1 | 2007 | 72334 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 1987 | 80636 | 0.000 |
Why?
|
| Cattle | 1 | 1984 | 3849 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1988 | 6019 | 0.000 |
Why?
|
| Cerebral Arterial Diseases | 1 | 1978 | 82 | 0.000 |
Why?
|
| Endarterectomy | 1 | 1978 | 196 | 0.000 |
Why?
|
| Probability | 1 | 1983 | 2477 | 0.000 |
Why?
|
| Adolescent | 2 | 2001 | 88319 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1994 | 9177 | 0.000 |
Why?
|
| Transcription Factors | 1 | 1996 | 12128 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 1986 | 5112 | 0.000 |
Why?
|
| DNA | 1 | 1987 | 7212 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1988 | 12974 | 0.000 |
Why?
|
| Neural Pathways | 1 | 1984 | 3058 | 0.000 |
Why?
|
| Child | 1 | 2001 | 80153 | 0.000 |
Why?
|
| Carotid Artery Diseases | 1 | 1978 | 877 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1996 | 54425 | 0.000 |
Why?
|
| Bipolar Disorder | 1 | 1988 | 5092 | 0.000 |
Why?
|
| Dementia | 1 | 1986 | 2686 | 0.000 |
Why?
|